A dimeric antigen-binding molecule specific for CD3 and CD19, composed of a first and a second polypeptide chain, each of the first and the second polypeptide chains comprising - a first domain V L A being a light chain variable domain specific for CD3; - a second domain V H B being a heavy chain variable domain specific for CD19; - a third domain V L B being a light chain variable domain specific for the CD19; and - a fourth domain V H A being a heavy chain variable domain specific for CD3, wherein - in the first and second polypeptide chain the first domain V L A is linked with the second domain V H B by a first linker L1, the second domain V H B is linked with the third domain V L B by a second linker L2 and the third domain V L B is linked with the fourth domain V H A by a third linker L3, wherein the linkers L1, L2 and L3 consist of 6, 7, 8, 9, 10, 11 or 12 amino acid residues, - said domains are arranged in each of said first and second polypeptide chains in the order V L A-V H B-V L B-V H A from the N-terminus to the C-terminus of said polypeptide chains in an orientation preventing intramolecular pairing, and - the first domain V L A of the first polypeptide chain is in association with the fourth domain V H A of the second polypeptide chain to form an antigen binding site for the first antigen A; - the second domain V H B of the first polypeptide chain is in association with the third domain V L B of the second polypeptide chain to form an antigen binding site for the second antigen B; - the third domain V L B of the first polypeptide chain is in association with the second domain V H B of the second polypeptide chain to form an antigen binding site for the second antigen B; and - the fourth domain V H A of the first polypeptide chain is in association with the first domain V L A of the second polypeptide chain to form an antigen binding site for the first antigen A. - a first domain V L A being a light chain variable domain specific for CD3; - a second domain V H B being a heavy chain variable domain specific for CD19; - a third domain V L B being a light chain variable domain specific for the CD19; and - a fourth domain V H A being a heavy chain variable domain specific for CD3, - in the first and second polypeptide chain the first domain V L A is linked with the second domain V H B by a first linker L1, the second domain V H B is linked with the third domain V L B by a second linker L2 and the third domain V L B is linked with the fourth domain V H A by a third linker L3, wherein the linkers L1, L2 and L3 consist of 6, 7, 8, 9, 10, 11 or 12 amino acid residues, - said domains are arranged in each of said first and second polypeptide chains in the order V L A-V H B-V L B-V H A from the N-terminus to the C-terminus of said polypeptide chains in an orientation preventing intramolecular pairing, and - the first domain V L A of the first polypeptide chain is in association with the fourth domain V H A of the second polypeptide chain to form an antigen binding site for the first antigen A; - the second domain V H B of the first polypeptide chain is in association with the third domain V L B of the second polypeptide chain to form an antigen binding site for the second antigen B; - the third domain V L B of the first polypeptide chain is in association with the second domain V H B of the second polypeptide chain to form an antigen binding site for the second antigen B; and - the fourth domain V H A of the first polypeptide chain is in association with the first domain V L A of the second polypeptide chain to form an antigen binding site for the first antigen A.